Business Context and Reporting Period
This Form 8-K was filed by Signal Genetics, Inc. on September 23, 2015. The filing reports the entry into a Material Definitive Agreement with a leading biopharmaceutical company. Note: The request metadata referenced "Viridian Therapeutics, Inc.," but the filing text explicitly identifies the registrant as Signal Genetics, Inc.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on a contractual agreement rather than periodic financial results.
Material Changes and Agreements
- Master Service Agreement: On September 23, 2015, the Company entered into a Master Service Agreement with a major biopharmaceutical partner.
- Scope of Work: The first two projects will utilize the Company's proprietary MyPRS® test to inform the clinical stage development of a novel treatment for multiple myeloma, including potential combination therapies.
- Timeline: Both projects are scheduled to commence prior to the end of 2015.
- Strategic Context: This represents the second master service agreement the Company has entered into during 2015.
Guidance, Outlook, and Risks
The filing includes a Regulation FD Disclosure referencing a press release regarding the partnership. The text does not provide specific financial guidance, quantitative outlook, or detailed risk factors beyond the standard disclaimer that the brief description of the agreement is not a complete description of rights and obligations.
Investor Verification Checklist
- Verify the identity of the "leading biopharmaceutical company" partner, as the filing does not name them.
- Review the full text of the Master Service Agreement (Exhibit 99.1) for specific financial terms, milestones, and payment structures.
- Confirm the status of the second master service agreement mentioned as having been entered into earlier in 2015.
- Assess the commercial viability and regulatory status of the MyPRS® test in the context of multiple myeloma treatments.